Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 3
2011 8
2012 5
2013 10
2014 9
2015 7
2016 20
2017 10
2018 10
2019 13
2020 12
2021 6
2022 8
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35058300

102 results

Results by year

Filters applied: . Clear all
Page 1
Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
Kurokawa R, Baba A, Kurokawa M, Capizzano A, Hassan O, Johnson T, Ota Y, Kim J, Hagiwara A, Moritani T, Srinivasan A. Kurokawa R, et al. AJNR Am J Neuroradiol. 2022 Feb;43(2):202-206. doi: 10.3174/ajnr.A7406. Epub 2022 Jan 20. AJNR Am J Neuroradiol. 2022. PMID: 35058300 Free PMC article.
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Patel KS, et al. Neurosurgery. 2020 Oct 15;87(5):931-938. doi: 10.1093/neuros/nyaa135. Neurosurgery. 2020. PMID: 32365185 Free PMC article.
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Ellingson BM, et al. Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27. Clin Cancer Res. 2017. PMID: 28655794 Free PMC article. Clinical Trial.
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, Von Deimling A, Van Den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P. Schell M, et al. Neuro Oncol. 2020 Nov 26;22(11):1667-1676. doi: 10.1093/neuonc/noaa120. Neuro Oncol. 2020. PMID: 32393964 Free PMC article. Clinical Trial.
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Pope WB, et al. J Neurooncol. 2012 Jul;108(3):491-8. doi: 10.1007/s11060-012-0847-y. Epub 2012 Mar 18. J Neurooncol. 2012. PMID: 22426926 Free PMC article.
Anti-angiogenic therapy for high-grade glioma.
Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M. Ameratunga M, et al. Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4. Cochrane Database Syst Rev. 2018. PMID: 30480778 Free PMC article.
102 results